STOCKHOLM, SWEDEN / RankWire.AI / – Karl Deisseroth, Peter Hegemann and Georg Nagel received the 2026 Nobel Prize in Physiology or Medicine for their pioneering discoveries that established the field of optogenetics. The Nobel Assembly at Karolinska Institutet announced the honor on October 5. Their groundbreaking work provided scientists with an exact method to control specific nerve cells using light. This technique now forms a fundamental part of research into brain circuits, behavior, memory, and disease. It has become one of the most vital tools in neuroscience experimentation.
Hegemann and Nagel contributed to revealing how channelrhodopsin functions in the green alga Chlamydomonas. This protein creates a light-sensitive channel embedded in a cell membrane. When blue light strikes, the channel opens, allowing charged ions to pass through. This ion flow can initiate electrical activity within the cell. Their experiments demonstrated that scientists could insert channelrhodopsin into other cells, making these cells responsive to light. This discovery laid the groundwork for controlling cell activity through light flashes.
Deisseroth then adapted this finding for neuroscience applications. In 2005, he proved that channelrhodopsin could make rat nerve cells respond to blue light. His research established that light could induce electrical signals in targeted neurons. Subsequent studies confirmed that this technique also worked in living animals. These results helped establish optogenetics as a practical approach for investigating how specific brain circuits influence activity and behavior. The method offers scientists far greater precision than earlier techniques.
Illumination technology revolutionizes brain research
Optogenetics employs genetic targeting combined with light-sensitive proteins. Researchers can utilize this method to activate or inhibit specific groups of nerve cells. Such control enables scientists to test how individual circuits contribute to movement, learning, emotions, and memory. According to the Nobel Assembly, this technique has transformed research on living brains. It also provides laboratories a means to link activity in particular cells with observable behavioral changes. Importantly, scientists can examine targeted cells without affecting large tissue areas simultaneously.
Today, optogenetics is widely used in studies of Parkinson’s disease, epilepsy, depression, addiction, and other disorders. Researchers are also exploring related strategies to address severe vision loss. Some experimental treatments aim to restore light responsiveness to retinal cells. These medical applications are still under investigation and are not yet standard practice. Currently, the most prominent role of the technique remains in research, where it allows for detailed examination of complex biological systems. Its scope has expanded beyond neuroscience into other fields of cell biology.
Three scientists awarded Nobel for pioneering work in optogenetics
Deisseroth is affiliated with Stanford University and the Howard Hughes Medical Institute in the United States. Hegemann is based at Humboldt University of Berlin. Nagel works at the University of Würzburg in Germany. The trio will share 12 million Swedish kronor. Their respective contributions represent separate yet interconnected stages in developing modern optogenetics—spanning the discovery of light-sensitive proteins, their characterization, and their application in controlling nerve cells.
Their work honors a scientific journey that began with a simple organism and has revolutionized modern brain research. Channelrhodopsin provided the molecular switch that enabled precise light control. Deisseroth’s efforts helped translate that switch into nerve cells and living brains. Today, optogenetics is used across neuroscience and various biological disciplines. The laureates will receive their Nobel medals and diplomas in Stockholm on December 10, aligning with the tradition marking the anniversary of Alfred Nobel’s death.